

Table 4.25

## Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Females by Race

| Histology <sup>a</sup>                                             | All Races |         | White   |         | Black  |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|--------------------------------------------------------------------|-----------|---------|---------|---------|--------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                    | Count     | Percent | Count   | Percent | Count  | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                                          | 293,300   | 99.4%   | 234,974 | 99.5%   | 31,773 | 99.3%   | 22,742                 | 99.2%   | 1,207                                          | 99.3%   | 29,953                | 99.3%   |
| Epidermoid carcinoma <sup>d</sup><br>(8051-8131)                   | 145       | 0.0%    | 117     | 0.0%    | 21     | 0.1%    | -                      | -       | -                                              | -       | -                     | -       |
| Adenocarcinoma <sup>e</sup>                                        | 287,384   | 97.4%   | 230,473 | 97.6%   | 30,801 | 96.3%   | 22,407                 | 97.7%   | 1,181                                          | 97.1%   | 29,328                | 97.2%   |
| Adenocarcinoma, NOS (8140)                                         | 2,176     | 0.7%    | 1,709   | 0.7%    | 296    | 0.9%    | 130                    | 0.6%    | -                                              | -       | 229                   | 0.8%    |
| Infiltrating duct carcinoma (8500)                                 | 216,104   | 73.2%   | 171,202 | 72.5%   | 24,088 | 75.3%   | 17,955                 | 78.3%   | 932                                            | 76.6%   | 22,451                | 74.4%   |
| Lobular carcinoma, NOS (8520)                                      | 26,726    | 9.1%    | 22,815  | 9.7%    | 2,319  | 7.2%    | 1,289                  | 5.6%    | 90                                             | 7.4%    | 2,264                 | 7.5%    |
| Inflammatory adenocarcinoma (8530)                                 | 1,003     | 0.3%    | 780     | 0.3%    | 159    | 0.5%    | 52                     | 0.2%    | -                                              | -       | 140                   | 0.5%    |
| Infiltrating duct mixed and infiltrating lobular mixed (8522-8524) | 27,371    | 9.3%    | 22,952  | 9.7%    | 2,372  | 7.4%    | 1,762                  | 7.7%    | 84                                             | 6.9%    | 2,892                 | 9.6%    |
| Mucinous adenocarcinoma (8480,8482)                                | 5,737     | 1.9%    | 4,469   | 1.9%    | 624    | 2.0%    | 563                    | 2.5%    | 24                                             | 2.0%    | 532                   | 1.8%    |
| Mucin-producing adenocarcinoma (8481)                              | 68        | 0.0%    | 48      | 0.0%    | -      | -       | -                      | -       | -                                              | -       | -                     | -       |
| Tubular adenocarcinoma (8211)                                      | 1,850     | 0.6%    | 1,636   | 0.7%    | 110    | 0.3%    | 92                     | 0.4%    | -                                              | -       | 143                   | 0.5%    |
| Papillary adenocarcinoma (8050,8260,8503,8504)                     | 1,754     | 0.6%    | 1,252   | 0.5%    | 288    | 0.9%    | 190                    | 0.8%    | -                                              | -       | 187                   | 0.6%    |
| Paget disease (8540-8543)                                          | 1,259     | 0.4%    | 998     | 0.4%    | 132    | 0.4%    | 107                    | 0.5%    | -                                              | -       | 146                   | 0.5%    |
| Other adenocarcinomas <sup>f</sup>                                 | 3,336     | 1.1%    | 2,612   | 1.1%    | 399    | 1.2%    | 262                    | 1.1%    | -                                              | -       | 339                   | 1.1%    |
| Other specific carcinomas <sup>g</sup>                             | 2,415     | 0.8%    | 1,797   | 0.8%    | 455    | 1.4%    | 136                    | 0.6%    | -                                              | -       | 288                   | 1.0%    |
| Medullary adenocarcinoma (8510-8513)                               | 815       | 0.3%    | 549     | 0.2%    | 212    | 0.7%    | 46                     | 0.2%    | -                                              | -       | 136                   | 0.5%    |
| Other <sup>h</sup>                                                 | 1,600     | 0.5%    | 1,248   | 0.5%    | 243    | 0.8%    | 90                     | 0.4%    | -                                              | -       | 152                   | 0.5%    |
| Unspecified, Carcinoma, NOS (8010-8011,8020-8022)                  | 3,356     | 1.1%    | 2,587   | 1.1%    | 496    | 1.6%    | 193                    | 0.8%    | -                                              | -       | 324                   | 1.1%    |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>f</sup> Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>g</sup> Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>h</sup> Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.25 - continued

## Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Females by Race

| Histology <sup>a</sup>                                                                                             | All Races |         | White   |         | Black  |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|--------------------------------------------------------------------------------------------------------------------|-----------|---------|---------|---------|--------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                                                                    | Count     | Percent | Count   | Percent | Count  | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Sarcoma and other soft tissue tumors (8680-8713, 8800-8921, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582) | 325       | 0.1%    | 243     | 0.1%    | 46     | 0.1%    | 31                     | 0.1%    | -                                              | -       | 25                    | 0.1%    |
| Hemangiosarcomas (9120-9126, 9170)                                                                                 | 157       | 0.1%    | 133     | 0.1%    | -      | -       | -                      | -       | -                                              | -       | -                     | -       |
| Other sarcomas <sup>d</sup>                                                                                        | 168       | 0.1%    | 110     | 0.0%    | 37     | 0.1%    | 18                     | 0.1%    | -                                              | -       | 19                    | 0.1%    |
| Other specific types (8720-8790, 8930-8936, 8950-9030, 9060-9110, 9260-9365, 9380-9539)                            | 741       | 0.3%    | 532     | 0.2%    | 89     | 0.3%    | 109                    | 0.5%    | -                                              | -       | 122                   | 0.4%    |
| Phyllodes tumor, malignant (9020)                                                                                  | 622       | 0.2%    | 442     | 0.2%    | 69     | 0.2%    | 101                    | 0.4%    | -                                              | -       | 106                   | 0.4%    |
| Other <sup>e</sup>                                                                                                 | 119       | 0.0%    | 90      | 0.0%    | 20     | 0.1%    | -                      | -       | -                                              | -       | 16                    | 0.1%    |
| Unspecified (8000-8005)                                                                                            | 657       | 0.2%    | 495     | 0.2%    | 90     | 0.3%    | 41                     | 0.2%    | -                                              | -       | 70                    | 0.2%    |
| Total <sup>f</sup>                                                                                                 | 295,023   | 100.0%  | 236,244 | 100.0%  | 31,998 | 100.0%  | 22,923                 | 100.0%  | 1,216                                          | 100.0%  | 30,170                | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

<sup>e</sup> Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

<sup>f</sup> Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26

Cancer of the Female Breast(*In Situ*)Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Females by Race

| Histology <sup>a</sup>                                            | All Races |         | White  |         | Black |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|-------------------------------------------------------------------|-----------|---------|--------|---------|-------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                   | Count     | Percent | Count  | Percent | Count | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Adenocarcinoma <sup>d</sup>                                       | 75,183    | 99.8%   | 58,643 | 99.8%   | 8,059 | 99.8%   | 7,338                  | 100.0%  | 246                                            | 100.0%  | 7,005                 | 99.8%   |
| Adenocarcinoma <i>in situ</i> NOS (8140/2)                        | -         | -       | -      | -       | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Ductal carcinoma <i>in situ</i> <sup>e</sup>                      | 63,846    | 84.8%   | 49,203 | 83.7%   | 7,070 | 87.5%   | 6,658                  | 90.7%   | 215                                            | 87.4%   | 6,014                 | 85.7%   |
| Cribiform carcinoma <i>in situ</i> (8201/2)                       | 6,409     | 8.5%    | 4,826  | 8.2%    | 748   | 9.3%    | 735                    | 10.0%   | 21                                             | 8.5%    | 615                   | 8.8%    |
| Ductal carcinoma <i>in situ</i> solid type(8230/2)                | 5,073     | 6.7%    | 4,042  | 6.9%    | 477   | 5.9%    | 479                    | 6.5%    | 18                                             | 7.3%    | 419                   | 6.0%    |
| Ductal carcinoma <i>in situ</i> NOS (8500/2)                      | 22,740    | 30.2%   | 17,793 | 30.3%   | 2,508 | 31.0%   | 2,074                  | 28.3%   | 78                                             | 31.7%   | 2,106                 | 30.0%   |
| Comedocarcinoma <i>in situ</i> (8501/2)                           | 6,030     | 8.0%    | 4,689  | 8.0%    | 614   | 7.6%    | 641                    | 8.7%    | 34                                             | 13.8%   | 562                   | 8.0%    |
| Ductal carcinoma <i>in situ</i> papillary(8503/2)                 | 1,156     | 1.5%    | 790    | 1.3%    | 202   | 2.5%    | 142                    | 1.9%    | -                                              | -       | 114                   | 1.6%    |
| Noninfiltrating intracystic carcinoma(8504/2)                     | 264       | 0.4%    | 171    | 0.3%    | 38    | 0.5%    | 52                     | 0.7%    | -                                              | -       | 27                    | 0.4%    |
| Ductal carcinoma <i>in situ</i> micropapillary(8507/2)            | 1,352     | 1.8%    | 1,064  | 1.8%    | 168   | 2.1%    | 105                    | 1.4%    | -                                              | -       | 130                   | 1.9%    |
| Intraductal with other types of carcinoma <i>in situ</i> (8523/2) | 20,649    | 27.4%   | 15,703 | 26.7%   | 2,305 | 28.5%   | 2,395                  | 32.6%   | 58                                             | 23.6%   | 2,028                 | 28.9%   |
| Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)          | 8,560     | 11.4%   | 7,239  | 12.3%   | 686   | 8.5%    | 441                    | 6.0%    | 26                                             | 10.6%   | 755                   | 10.8%   |
| Lobular carcinoma <i>in situ</i> NOS (8520/2)                     | 8,538     | 11.3%   | 7,220  | 12.3%   | 683   | 8.5%    | 441                    | 6.0%    | 26                                             | 10.6%   | 754                   | 10.7%   |
| Lobular CIS <sup>f</sup> with other CIS <sup>f</sup> (8524/2)     | 22        | 0.0%    | 19     | 0.0%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Intraductal and lobular <i>in situ</i> carcinoma (8522/2)         | 2,261     | 3.0%    | 1,819  | 3.1%    | 239   | 3.0%    | 175                    | 2.4%    | -                                              | -       | 188                   | 2.7%    |
| Other adenocarcinomas <sup>g</sup>                                | 510       | 0.7%    | 378    | 0.6%    | 64    | 0.8%    | 62                     | 0.8%    | -                                              | -       | 48                    | 0.7%    |
| Other <i>in situ</i> histologies <sup>h</sup>                     | 137       | 0.2%    | 108    | 0.2%    | 20    | 0.2%    | -                      | -       | -                                              | -       | -                     | -       |
| Total                                                             | 75,320    | 100.0%  | 58,751 | 100.0%  | 8,079 | 100.0%  | 7,341                  | 100.0%  | 246                                            | 100.0%  | 7,018                 | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

<sup>g</sup> CIS = Carcinoma *in situ*.

<sup>h</sup> Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>i</sup> Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

## Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Females by Race

| Histology <sup>a</sup>                                                                        | All Races |         | White  |         | Black |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|-----------------------------------------------------------------------------------------------|-----------|---------|--------|---------|-------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                                               | Count     | Percent | Count  | Percent | Count | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                                                                     | 16,473    | 98.1%   | 12,363 | 98.3%   | 2,317 | 97.6%   | 1,447                  | 98.2%   | 122                                            | 97.6%   | 3,634                 | 98.2%   |
| Epidermoid carcinoma <sup>d</sup><br>(8050-8131)                                              | 11,051    | 65.8%   | 8,034  | 63.9%   | 1,818 | 76.6%   | 965                    | 65.5%   | 75                                             | 60.0%   | 2,483                 | 67.1%   |
| Squamous cell carcinoma<br>(8070)                                                             | 7,658     | 45.6%   | 5,509  | 43.8%   | 1,317 | 55.5%   | 665                    | 45.1%   | 57                                             | 45.6%   | 1,563                 | 42.3%   |
| Squamous cell,<br>keratinizing (8071)                                                         | 1,152     | 6.9%    | 833    | 6.6%    | 197   | 8.3%    | 101                    | 6.9%    | -                                              | -       | 305                   | 8.2%    |
| Squamous cell,<br>non-keratinizing (8072)                                                     | 1,493     | 8.9%    | 1,132  | 9.0%    | 202   | 8.5%    | 136                    | 9.2%    | -                                              | -       | 427                   | 11.5%   |
| Squamous cell,<br>Microinvasive (8076)                                                        | 499       | 3.0%    | 376    | 3.0%    | 61    | 2.6%    | 42                     | 2.9%    | -                                              | -       | 131                   | 3.5%    |
| Other (8050-8069,<br>8073-8075,8077-8131)                                                     | 249       | 1.5%    | 184    | 1.5%    | 41    | 1.7%    | 21                     | 1.4%    | -                                              | -       | 57                    | 1.5%    |
| Adenocarcinoma <sup>e</sup>                                                                   | 4,699     | 28.0%   | 3,800  | 30.2%   | 380   | 16.0%   | 429                    | 29.1%   | 37                                             | 29.6%   | 987                   | 26.7%   |
| Adenocarcinoma, NOS (8140)                                                                    | 2,511     | 15.0%   | 2,042  | 16.2%   | 198   | 8.3%    | 220                    | 14.9%   | 17                                             | 13.6%   | 538                   | 14.5%   |
| Adenosquamous (8560,8570)                                                                     | 565       | 3.4%    | 439    | 3.5%    | 59    | 2.5%    | 60                     | 4.1%    | -                                              | -       | 128                   | 3.5%    |
| Other adenocarcinomas <sup>f</sup>                                                            | 1,623     | 9.7%    | 1,319  | 10.5%   | 123   | 5.2%    | 149                    | 10.1%   | -                                              | -       | 321                   | 8.7%    |
| Other specific carcinomas <sup>g</sup>                                                        | 264       | 1.6%    | 209    | 1.7%    | 33    | 1.4%    | 19                     | 1.3%    | -                                              | -       | 57                    | 1.5%    |
| Unspecified, Carcinoma, NOS<br>(8010-8011,8020-8022)                                          | 459       | 2.7%    | 320    | 2.5%    | 86    | 3.6%    | 34                     | 2.3%    | -                                              | -       | 107                   | 2.9%    |
| Sarcoma <sup>h</sup>                                                                          | 61        | 0.4%    | 42     | 0.3%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Other specific types<br>(8720-8790,8930-8936,<br>8950-9030,9060-9110,<br>9260-9365,9380-9539) | 162       | 1.0%    | 107    | 0.9%    | 30    | 1.3%    | 17                     | 1.2%    | -                                              | -       | 32                    | 0.9%    |
| Unspecified (8000-8005)                                                                       | 89        | 0.5%    | 65     | 0.5%    | -     | -       | -                      | -       | -                                              | -       | 20                    | 0.5%    |
| Total                                                                                         | 16,785    | 100.0%  | 12,577 | 100.0%  | 2,373 | 100.0%  | 1,473                  | 100.0%  | 125                                            | 100.0%  | 3,699                 | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>e</sup> Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

<sup>g</sup> Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

<sup>h</sup> Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

## Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Both Sexes by Race

| Histology <sup>a</sup>                                                                                                               | All Races |         | White   |         | Black  |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|--------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|---------|---------|--------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                                                                                      | Count     | Percent | Count   | Percent | Count  | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                                                                                                            | 180,720   | 99.4%   | 141,644 | 99.5%   | 21,747 | 99.4%   | 14,393                 | 99.4%   | 976                                            | 99.7%   | 18,469                | 99.4%   |
| Epidermoid carcinoma <sup>d</sup><br>(8051-8131)                                                                                     | 1,113     | 0.6%    | 942     | 0.7%    | 130    | 0.6%    | 21                     | 0.1%    | -                                              | -       | 96                    | 0.5%    |
| Squamous cell carcinoma<br>(8070-8078,8083-8084)                                                                                     | 1,054     | 0.6%    | 893     | 0.6%    | 125    | 0.6%    | 21                     | 0.1%    | -                                              | -       | 90                    | 0.5%    |
| Adenocarcinoma<br>(8050,8140-8147,<br>8160-8162,8180-8221,<br>8250-8507,8520-8551,8560,<br>8570-8574,8576,8940-8941)                 | 169,224   | 93.1%   | 133,801 | 94.0%   | 19,702 | 90.1%   | 13,345                 | 92.2%   | 905                                            | 92.4%   | 17,173                | 92.4%   |
| Adenocarcinoma, NOS<br>(8140)                                                                                                        | 116,238   | 63.9%   | 91,560  | 64.3%   | 13,674 | 62.5%   | 9,533                  | 65.8%   | 660                                            | 67.4%   | 11,872                | 63.9%   |
| Adenocarcinoma in<br>adenomatous polyp (8210)                                                                                        | 15,009    | 8.3%    | 11,773  | 8.3%    | 1,624  | 7.4%    | 1,283                  | 8.9%    | 85                                             | 8.7%    | 1,345                 | 7.2%    |
| Adenocarcinoma in<br>villous adenoma (8261)                                                                                          | 4,443     | 2.4%    | 3,585   | 2.5%    | 464    | 2.1%    | 330                    | 2.3%    | 18                                             | 1.8%    | 575                   | 3.1%    |
| Mucinous adenocarcinoma<br>(8470-8473,8480,8482)                                                                                     | 11,678    | 6.4%    | 9,649   | 6.8%    | 1,221  | 5.6%    | 698                    | 4.8%    | 53                                             | 5.4%    | 1,269                 | 6.8%    |
| Mucin-producing<br>adenocarcinoma (8481)                                                                                             | 1,855     | 1.0%    | 1,502   | 1.1%    | 253    | 1.2%    | 93                     | 0.6%    | -                                              | -       | 172                   | 0.9%    |
| Signet ring<br>adenocarcinoma (8490)                                                                                                 | 2,039     | 1.1%    | 1,675   | 1.2%    | 197    | 0.9%    | 144                    | 1.0%    | -                                              | -       | 214                   | 1.2%    |
| Other adenocarcinomas <sup>e</sup>                                                                                                   | 17,962    | 9.9%    | 14,057  | 9.9%    | 2,269  | 10.4%   | 1,264                  | 8.7%    | 78                                             | 8.0%    | 1,726                 | 9.3%    |
| Other specific carcinomas<br>(8012-8015,8030-8046,<br>8150-8155,8170-8175,<br>8230-8249,8508,8510-8513,<br>8561-8562,8575,8580-8671) | 8,787     | 4.8%    | 5,665   | 4.0%    | 1,711  | 7.8%    | 914                    | 6.3%    | 50                                             | 5.1%    | 1,033                 | 5.6%    |
| Neuroendocrine carcinoid<br>(8240-8245)                                                                                              | 6,693     | 3.7%    | 4,080   | 2.9%    | 1,409  | 6.4%    | 758                    | 5.2%    | 42                                             | 4.3%    | 842                   | 4.5%    |
| Other <sup>f</sup>                                                                                                                   | 2,094     | 1.2%    | 1,585   | 1.1%    | 302    | 1.4%    | 156                    | 1.1%    | -                                              | -       | 191                   | 1.0%    |
| Unspecified, Carcinoma, NOS<br>(8010-8011, 8020-8022)                                                                                | 1,596     | 0.9%    | 1,236   | 0.9%    | 204    | 0.9%    | 113                    | 0.8%    | 19                                             | 1.9%    | 167                   | 0.9%    |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>f</sup> Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

## Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Both Sexes by Race

| Histology <sup>a</sup>                                                                                                        | All Races |         | White   |         | Black  |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|-------------------------------------------------------------------------------------------------------------------------------|-----------|---------|---------|---------|--------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                                                                               | Count     | Percent | Count   | Percent | Count  | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Sarcoma and other soft tissue tumors (8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582) | 110       | 0.1%    | 89      | 0.1%    | -      | -       | -                      | -       | -                                              | -       | 16                    | 0.1%    |
| Other specific types (8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539)                            | 293       | 0.2%    | 202     | 0.1%    | 45     | 0.2%    | 44                     | 0.3%    | -                                              | -       | 32                    | 0.2%    |
| Unspecified (8000-8005)                                                                                                       | 648       | 0.4%    | 480     | 0.3%    | 61     | 0.3%    | 40                     | 0.3%    | -                                              | -       | 66                    | 0.4%    |
| Total <sup>d</sup>                                                                                                            | 181,771   | 100.0%  | 142,415 | 100.0%  | 21,868 | 100.0%  | 14,481                 | 100.0%  | 979                                            | 100.0%  | 18,583                | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

## Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Both Sexes by Race

| Histology <sup>a</sup>                                | All Races |         | White  |         | Black |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|-------------------------------------------------------|-----------|---------|--------|---------|-------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                       | Count     | Percent | Count  | Percent | Count | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                             | 18,629    | 99.0%   | 15,657 | 99.0%   | 1,957 | 99.2%   | 822                    | 99.0%   | 78                                             | 100.0%  | 1,392                 | 98.8%   |
| Epidermoid carcinoma <sup>d</sup><br>(8051-8131)      | 6,214     | 33.0%   | 4,016  | 25.4%   | 1,571 | 79.7%   | 567                    | 68.3%   | 26                                             | 33.3%   | 509                   | 36.1%   |
| Squamous cell carcinoma<br>(8070-8078, 8083-8084)     | 6,195     | 32.9%   | 4,003  | 25.3%   | 1,565 | 79.4%   | 567                    | 68.3%   | 26                                             | 33.3%   | 508                   | 36.1%   |
| Adenocarcinoma <sup>e</sup>                           | 11,565    | 61.5%   | 10,912 | 69.0%   | 313   | 15.9%   | 221                    | 26.6%   | 47                                             | 60.3%   | 818                   | 58.1%   |
| Other specific carcinomas <sup>f</sup>                | 282       | 1.5%    | 235    | 1.5%    | 31    | 1.6%    | -                      | -       | -                                              | -       | 20                    | 1.4%    |
| Unspecified, Carcinoma, NOS<br>(8010-8011, 8020-8022) | 568       | 3.0%    | 494    | 3.1%    | 42    | 2.1%    | 22                     | 2.7%    | -                                              | -       | 45                    | 3.2%    |
| Other specific types <sup>g</sup>                     | 59        | 0.3%    | 50     | 0.3%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Unspecified (8000-8005)                               | 121       | 0.6%    | 103    | 0.7%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Total                                                 | 18,809    | 100.0%  | 15,810 | 100.0%  | 1,972 | 100.0%  | 830                    | 100.0%  | 78                                             | 100.0%  | 1,409                 | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>f</sup> Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>g</sup> Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

Other specific types includes sarcomas and other soft tissue tumors.

Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

## Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Both Sexes by Race

| Histology <sup>a</sup>                                                                           | All Races |         | White  |         | Black |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|--------------------------------------------------------------------------------------------------|-----------|---------|--------|---------|-------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                                                  | Count     | Percent | Count  | Percent | Count | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma (8010-8576)                                                                            | 22,463    | 97.1%   | 15,854 | 96.9%   | 2,909 | 98.1%   | 3,327                  | 97.7%   | 203                                            | 97.6%   | 3,702                 | 95.2%   |
| Hepatocellular carcinoma <sup>d</sup><br>(8170-8175)                                             | 17,223    | 74.5%   | 11,792 | 72.1%   | 2,449 | 82.6%   | 2,680                  | 78.7%   | 160                                            | 76.9%   | 2,920                 | 75.1%   |
| Cholangiocarcinoma<br>(8032-8033, 8070-8071,<br>8140-8141, 8160, 8260,<br>8480-8481, 8490, 8560) | 4,252     | 18.4%   | 3,341  | 20.4%   | 344   | 11.6%   | 512                    | 15.0%   | 35                                             | 16.8%   | 613                   | 15.8%   |
| Other carcinoma <sup>e</sup>                                                                     | 988       | 4.3%    | 721    | 4.4%    | 116   | 3.9%    | 135                    | 4.0%    | -                                              | -       | 169                   | 4.3%    |
| Other specific carcinoma <sup>f</sup>                                                            | 614       | 2.7%    | 453    | 2.8%    | 68    | 2.3%    | 86                     | 2.5%    | -                                              | -       | 105                   | 2.7%    |
| Unspecified, Carcinoma, NOS<br>(8010, 8020-8022, 8031,<br>8046, 8050)                            | 374       | 1.6%    | 268    | 1.6%    | 48    | 1.6%    | 49                     | 1.4%    | -                                              | -       | 64                    | 1.6%    |
| Hepatoblastoma (8970)                                                                            | 229       | 1.0%    | 172    | 1.1%    | 19    | 0.6%    | 29                     | 0.9%    | -                                              | -       | 83                    | 2.1%    |
| Sarcoma <sup>g</sup>                                                                             | 219       | 0.9%    | 174    | 1.1%    | 18    | 0.6%    | 24                     | 0.7%    | -                                              | -       | 43                    | 1.1%    |
| Hemangiosarcoma (9120)                                                                           | 86        | 0.4%    | 68     | 0.4%    | -     | -       | -                      | -       | -                                              | -       | 17                    | 0.4%    |
| Other sarcomas <sup>h</sup>                                                                      | 133       | 0.6%    | 106    | 0.6%    | -     | -       | -                      | -       | -                                              | -       | 26                    | 0.7%    |
| Other specific types<br>(8720, 8980, 8991, 9061,<br>9064, 9070-9071, 9080,<br>9100)              | 41        | 0.2%    | 31     | 0.2%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Unspecified (8000-8004)                                                                          | 169       | 0.7%    | 133    | 0.8%    | -     | -       | 21                     | 0.6%    | -                                              | -       | 45                    | 1.2%    |
| Total <sup>d</sup>                                                                               | 23,123    | 100.0%  | 16,366 | 100.0%  | 2,965 | 100.0%  | 3,406                  | 100.0%  | 208                                            | 100.0%  | 3,887                 | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

<sup>f</sup> Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

<sup>g</sup> Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

<sup>h</sup> Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

<sup>i</sup> Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

## Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Both Sexes by Race

| Histology <sup>a</sup>                      | All Races |         |         | White   |         | Black  |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|---------------------------------------------|-----------|---------|---------|---------|---------|--------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                             | Rate      | Count   | Percent | Count   | Percent | Count  | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                   | 51.9      | 226,896 | 99.7%   | 186,528 | 99.7%   | 25,544 | 99.7%   | 13,248                 | 99.7%   | 774                                            | 99.1%   | 12,809                | 99.4%   |
| Small cell (8002,8041-8045)                 | 6.8       | 30,156  | 13.3%   | 26,229  | 14.0%   | 2,660  | 10.4%   | 1,038                  | 7.8%    | 141                                            | 18.1%   | 1,430                 | 11.1%   |
| Non-small cell                              | 43.5      | 189,727 | 83.4%   | 154,665 | 82.7%   | 21,991 | 85.8%   | 11,775                 | 88.6%   | 608                                            | 77.8%   | 10,843                | 84.2%   |
| Squamous and transitional cell <sup>d</sup> | 11.9      | 51,375  | 22.6%   | 42,831  | 22.9%   | 6,133  | 23.9%   | 2,059                  | 15.5%   | 194                                            | 24.8%   | 2,393                 | 18.6%   |
| Adenocarcinoma <sup>e</sup>                 | 22.5      | 98,473  | 43.3%   | 79,151  | 42.3%   | 10,976 | 42.8%   | 7,720                  | 58.1%   | 260                                            | 33.3%   | 5,987                 | 46.5%   |
| Large cell <sup>f</sup>                     | 1.1       | 4,672   | 2.1%    | 3,817   | 2.0%    | 635    | 2.5%    | 197                    | 1.5%    | -                                              | -       | 228                   | 1.8%    |
| Non-small cell carcinoma <sup>g</sup>       | 5.5       | 23,952  | 10.5%   | 19,243  | 10.3%   | 3,178  | 12.4%   | 1,318                  | 9.9%    | 118                                            | 15.1%   | 1,375                 | 10.7%   |
| Other specified carcinomas <sup>h</sup>     | 2.6       | 11,255  | 4.9%    | 9,623   | 5.1%    | 1,069  | 4.2%    | 481                    | 3.6%    | 25                                             | 3.2%    | 860                   | 6.7%    |
| Carcinoma, NOS <sup>i</sup>                 | 1.6       | 7,013   | 3.1%    | 5,634   | 3.0%    | 893    | 3.5%    | 435                    | 3.3%    | 25                                             | 3.2%    | 536                   | 4.2%    |
| Sarcoma <sup>j</sup>                        | 0.1       | 433     | 0.2%    | 353     | 0.2%    | 47     | 0.2%    | 24                     | 0.2%    | -                                              | -       | 52                    | 0.4%    |
| Other specified types <sup>k</sup>          | 0.0       | 198     | 0.1%    | 160     | 0.1%    | 27     | 0.1%    | -                      | -       | -                                              | -       | 22                    | 0.2%    |
| Total                                       | 52.0      | 227,527 | 100.0%  | 187,041 | 100.0%  | 25,618 | 100.0%  | 13,283                 | 100.0%  | 781                                            | 100.0%  | 12,883                | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

<sup>e</sup> Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

<sup>f</sup> Large cell includes histologies 8012-8014, 8021, 8034, 8082.

<sup>g</sup> Non-small cell carcinoma includes histology 8046.

<sup>h</sup> Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

<sup>i</sup> Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

<sup>j</sup> Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

<sup>k</sup> Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

## Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012

Males by Race

| Histology <sup>a</sup>                      | All Races |         |         | White  |         | Black  |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|---------------------------------------------|-----------|---------|---------|--------|---------|--------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                             | Rate      | Count   | Percent | Count  | Percent | Count  | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                   | 61.7      | 120,021 | 99.7%   | 97,398 | 99.7%   | 14,323 | 99.7%   | 7,457                  | 99.7%   | 401                                            | 99.5%   | 6,749                 | 99.4%   |
| Small cell (8002,8041-8045)                 | 7.5       | 15,056  | 12.5%   | 12,917 | 13.2%   | 1,353  | 9.4%    | 682                    | 9.1%    | 64                                             | 15.9%   | 754                   | 11.1%   |
| Non-small cell                              | 52.1      | 101,018 | 83.9%   | 81,392 | 83.3%   | 12,413 | 86.4%   | 6,503                  | 87.0%   | 326                                            | 80.9%   | 5,681                 | 83.6%   |
| Squamous and transitional cell <sup>d</sup> | 16.8      | 32,229  | 26.8%   | 26,568 | 27.2%   | 3,934  | 27.4%   | 1,494                  | 20.0%   | 117                                            | 29.0%   | 1,514                 | 22.3%   |
| Adenocarcinoma <sup>e</sup>                 | 24.4      | 47,518  | 39.5%   | 37,692 | 38.6%   | 5,726  | 39.9%   | 3,790                  | 50.7%   | 125                                            | 31.0%   | 2,827                 | 41.6%   |
| Large cell <sup>f</sup>                     | 1.3       | 2,631   | 2.2%    | 2,125  | 2.2%    | 370    | 2.6%    | 124                    | 1.7%    | -                                              | -       | 139                   | 2.0%    |
| Non-small cell carcinoma <sup>g</sup>       | 6.9       | 13,474  | 11.2%   | 10,681 | 10.9%   | 1,847  | 12.9%   | 829                    | 11.1%   | 68                                             | 16.9%   | 799                   | 11.8%   |
| Other specified carcinomas <sup>h</sup>     | 2.6       | 5,166   | 4.3%    | 4,326  | 4.4%    | 536    | 3.7%    | 266                    | 3.6%    | -                                              | -       | 402                   | 5.9%    |
| Carcinoma, NOS <sup>i</sup>                 | 2.1       | 3,947   | 3.3%    | 3,089  | 3.2%    | 557    | 3.9%    | 272                    | 3.6%    | -                                              | -       | 314                   | 4.6%    |
| Sarcoma <sup>j</sup>                        | 0.1       | 239     | 0.2%    | 200    | 0.2%    | 25     | 0.2%    | -                      | -       | -                                              | -       | 28                    | 0.4%    |
| Other specified types <sup>k</sup>          | 0.1       | 126     | 0.1%    | 105    | 0.1%    | -      | -       | -                      | -       | -                                              | -       | -                     | -       |
| Total                                       | 61.9      | 120,386 | 100.0%  | 97,703 | 100.0%  | 14,361 | 100.0%  | 7,476                  | 100.0%  | 403                                            | 100.0%  | 6,792                 | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

<sup>e</sup> Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

<sup>f</sup> Large cell includes histologies 8012-8014, 8021, 8034, 8082.

<sup>g</sup> Non-small cell carcinoma includes histology 8046.

<sup>h</sup> Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

<sup>i</sup> Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

<sup>j</sup> Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

<sup>k</sup> Other specified types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

## Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Females by Race

| Histology <sup>a</sup>                      | All Races |         |         | White  |         | Black  |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|---------------------------------------------|-----------|---------|---------|--------|---------|--------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                             | Rate      | Count   | Percent | Count  | Percent | Count  | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                   | 44.5      | 106,875 | 99.8%   | 89,130 | 99.8%   | 11,221 | 99.7%   | 5,791                  | 99.7%   | 373                                            | 98.7%   | 6,060                 | 99.5%   |
| Small cell (8002,8041-8045)                 | 6.2       | 15,100  | 14.1%   | 13,312 | 14.9%   | 1,307  | 11.6%   | 356                    | 6.1%    | 77                                             | 20.4%   | 676                   | 11.1%   |
| Non-small cell                              | 37.0      | 88,709  | 82.8%   | 73,273 | 82.0%   | 9,578  | 85.1%   | 5,272                  | 90.8%   | 282                                            | 74.6%   | 5,162                 | 84.7%   |
| Squamous and transitional cell <sup>d</sup> | 8.1       | 19,146  | 17.9%   | 16,263 | 18.2%   | 2,199  | 19.5%   | 565                    | 9.7%    | 77                                             | 20.4%   | 879                   | 14.4%   |
| Adenocarcinoma <sup>e</sup>                 | 21.2      | 50,955  | 47.6%   | 41,459 | 46.4%   | 5,250  | 46.6%   | 3,930                  | 67.7%   | 135                                            | 35.7%   | 3,160                 | 51.9%   |
| Large cell <sup>f</sup>                     | 0.8       | 2,041   | 1.9%    | 1,692  | 1.9%    | 265    | 2.4%    | 73                     | 1.3%    | -                                              | -       | 89                    | 1.5%    |
| Non-small cell carcinoma <sup>g</sup>       | 4.4       | 10,478  | 9.8%    | 8,562  | 9.6%    | 1,331  | 11.8%   | 489                    | 8.4%    | 50                                             | 13.2%   | 576                   | 9.5%    |
| Other specified carcinomas <sup>h</sup>     | 2.6       | 6,089   | 5.7%    | 5,297  | 5.9%    | 533    | 4.7%    | 215                    | 3.7%    | -                                              | -       | 458                   | 7.5%    |
| Carcinoma, NOS <sup>i</sup>                 | 1.3       | 3,066   | 2.9%    | 2,545  | 2.8%    | 336    | 3.0%    | 163                    | 2.8%    | -                                              | -       | 222                   | 3.6%    |
| Sarcoma <sup>j</sup>                        | 0.1       | 194     | 0.2%    | 153    | 0.2%    | 22     | 0.2%    | -                      | -       | -                                              | -       | 24                    | 0.4%    |
| Other specified types <sup>k</sup>          | 0.0       | 72      | 0.1%    | 55     | 0.1%    | -      | -       | -                      | -       | -                                              | -       | -                     | -       |
| Total                                       | 44.6      | 107,141 | 100.0%  | 89,338 | 100.0%  | 11,257 | 100.0%  | 5,807                  | 100.0%  | 378                                            | 100.0%  | 6,091                 | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

<sup>e</sup> Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

<sup>f</sup> Large cell includes histologies 8012-8014, 8021, 8034, 8082.

<sup>g</sup> Non-small cell carcinoma includes histology 8046.

<sup>h</sup> Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

<sup>i</sup> Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

<sup>j</sup> Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

<sup>k</sup> Other specified types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

## Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
All Races, Both Sexes, by site

| Histology <sup>a</sup>                             | Oral Cavity and Pharynx |         | Lip   |         | Tongue |         | Salivary Gland |         | Floor of Mouth |         |
|----------------------------------------------------|-------------------------|---------|-------|---------|--------|---------|----------------|---------|----------------|---------|
|                                                    | Count                   | Percent | Count | Percent | Count  | Percent | Count          | Percent | Count          | Percent |
| Epidermoid carcinoma <sup>b</sup> (8051-8131)      | 41,634                  | 84.3%   | 2,759 | 94.4%   | 14,414 | 97.3%   | 1,212          | 21.9%   | 2,411          | 95.4%   |
| Squamous cell carcinoma (8070-8078, 8083-8084)     | 40,643                  | 82.3%   | 2,645 | 90.5%   | 14,168 | 95.6%   | 1,160          | 20.9%   | 2,385          | 94.4%   |
| Adenocarcinoma <sup>c</sup>                        | 5,033                   | 10.2%   | 116   | 4.0%    | 223    | 1.5%    | 3,392          | 61.2%   | 83             | 3.3%    |
| Other specific carcinomas <sup>d</sup>             | 514                     | 1.0%    | -     | -       | 37     | 0.2%    | 306            | 5.5%    | -              | -       |
| Unspecified, Carcinoma, NOS (8010-8011, 8020-8022) | 1,611                   | 3.3%    | -     | -       | 79     | 0.5%    | 414            | 7.5%    | -              | -       |
| Sarcoma and soft tissue <sup>e</sup>               | 153                     | 0.3%    | -     | -       | 19     | 0.1%    | 33             | 0.6%    | -              | -       |
| Other specific types <sup>f</sup>                  | 264                     | 0.5%    | 17    | 0.6%    | 16     | 0.1%    | 115            | 2.1%    | -              | -       |
| Unspecified (8000-8005)                            | 183                     | 0.4%    | -     | -       | 33     | 0.2%    | 70             | 1.3%    | -              | -       |
| Total                                              | 49,393                  | 100.0%  | 2,923 | 100.0%  | 14,821 | 100.0%  | 5,542          | 100.0%  | 2,526          | 100.0%  |

  

| Histology <sup>a</sup>                             | Gum and Other Mouth |         | Nasopharynx |         | Oropharynx and Tonsil |         | Hypopharynx |         | Other Oral Cavity and Pharynx |         |
|----------------------------------------------------|---------------------|---------|-------------|---------|-----------------------|---------|-------------|---------|-------------------------------|---------|
|                                                    | Count               | Percent | Count       | Percent | Count                 | Percent | Count       | Percent | Count                         | Percent |
| Epidermoid carcinoma <sup>b</sup> (8051-8131)      | 5,360               | 80.9%   | 1,717       | 62.4%   | 10,307                | 97.5%   | 2,712       | 96.9%   | 742                           | 89.1%   |
| Squamous cell carcinoma (8070-8078, 8083-8084)     | 5,111               | 77.1%   | 1,566       | 56.9%   | 10,185                | 96.4%   | 2,691       | 96.1%   | 732                           | 87.9%   |
| Adenocarcinoma <sup>c</sup>                        | 1,034               | 15.6%   | 87          | 3.2%    | 64                    | 0.6%    | 16          | 0.6%    | 18                            | 2.2%    |
| Other specific carcinomas <sup>d</sup>             | 42                  | 0.6%    | 39          | 1.4%    | 41                    | 0.4%    | 21          | 0.8%    | -                             | -       |
| Unspecified, Carcinoma, NOS (8010-8011, 8020-8022) | 57                  | 0.9%    | 843         | 30.6%   | 121                   | 1.1%    | 35          | 1.3%    | 35                            | 4.2%    |
| Sarcoma and soft tissue <sup>e</sup>               | 31                  | 0.5%    | 34          | 1.2%    | -                     | -       | -           | -       | -                             | -       |
| Other specific types <sup>f</sup>                  | 86                  | 1.3%    | 16          | 0.6%    | -                     | -       | -           | -       | -                             | -       |
| Unspecified (8000-8005)                            | 17                  | 0.3%    | 17          | 0.6%    | 20                    | 0.2%    | -           | -       | -                             | -       |
| Total                                              | 6,628               | 100.0%  | 2,753       | 100.0%  | 10,568                | 100.0%  | 2,799       | 100.0%  | 833                           | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>c</sup> Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>d</sup> Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

<sup>e</sup> Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

<sup>f</sup> Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

## Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Females by Race

| Histology <sup>a</sup>                                | All Races |         | White  |         | Black |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|-------------------------------------------------------|-----------|---------|--------|---------|-------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                       | Count     | Percent | Count  | Percent | Count | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                             | 24,670    | 91.6%   | 20,525 | 92.2%   | 1,973 | 87.8%   | 1,909                  | 90.6%   | 124                                            | 92.5%   | 3,009                 | 87.2%   |
| Epidermoid carcinoma <sup>d</sup><br>(8051-8131)      | 202       | 0.8%    | 157    | 0.7%    | 20    | 0.9%    | 22                     | 1.0%    | -                                              | -       | 34                    | 1.0%    |
| Adenocarcinoma <sup>e</sup>                           | 22,644    | 84.1%   | 18,937 | 85.0%   | 1,713 | 76.2%   | 1,765                  | 83.8%   | 111                                            | 82.8%   | 2,711                 | 78.5%   |
| Adenocarcinoma, NOS (8140)                            | 3,108     | 11.5%   | 2,515  | 11.3%   | 399   | 17.8%   | 169                    | 8.0%    | -                                              | -       | 318                   | 9.2%    |
| Papillary adenocarcinoma,<br>NOS (8050,8260)          | 357       | 1.3%    | 304    | 1.4%    | 34    | 1.5%    | -                      | -       | -                                              | -       | 48                    | 1.4%    |
| Clear cell adenocarcinoma<br>(8310,9110)              | 1,434     | 5.3%    | 1,098  | 4.9%    | 60    | 2.7%    | 264                    | 12.5%   | -                                              | -       | 161                   | 4.7%    |
| Endometrioid carcinoma<br>(8380-8383,8570)            | 2,640     | 9.8%    | 2,201  | 9.9%    | 131   | 5.8%    | 277                    | 13.1%   | -                                              | -       | 401                   | 11.6%   |
| Cystadenocarcinoma, NOS<br>(8440,8450)                | 98        | 0.4%    | 80     | 0.4%    | -     | -       | -                      | -       | -                                              | -       | 17                    | 0.5%    |
| Serous cystadenocarcinoma<br>(8441)                   | 6,303     | 23.4%   | 5,388  | 24.2%   | 433   | 19.3%   | 409                    | 19.4%   | 41                                             | 30.6%   | 663                   | 19.2%   |
| Papillary serous<br>cystadenocarcinoma<br>(8460-8462) | 5,863     | 21.8%   | 5,019  | 22.5%   | 452   | 20.1%   | 347                    | 16.5%   | 26                                             | 19.4%   | 712                   | 20.6%   |
| Mucinous cystadenocarcinoma<br>(8470-8473)            | 389       | 1.4%    | 315    | 1.4%    | 27    | 1.2%    | 43                     | 2.0%    | -                                              | -       | 60                    | 1.7%    |
| Mucinous adenocarcinoma<br>(8480,8482)                | 984       | 3.7%    | 779    | 3.5%    | 84    | 3.7%    | 107                    | 5.1%    | -                                              | -       | 148                   | 4.3%    |
| Mucin-producing<br>adenocarcinoma(8481)               | 41        | 0.2%    | 33     | 0.1%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Other adenocarcinoma <sup>f</sup>                     | 1,427     | 5.3%    | 1,205  | 5.4%    | 77    | 3.4%    | 127                    | 6.0%    | -                                              | -       | 179                   | 5.2%    |
| Other specific carcinomas <sup>g</sup>                | 640       | 2.4%    | 454    | 2.0%    | 128   | 5.7%    | 45                     | 2.1%    | -                                              | -       | 100                   | 2.9%    |
| Stromal cell tumor<br>(8620-8631,8650)                | 451       | 1.7%    | 304    | 1.4%    | 105   | 4.7%    | 30                     | 1.4%    | -                                              | -       | 70                    | 2.0%    |
| Other <sup>h</sup>                                    | 189       | 0.7%    | 150    | 0.7%    | 23    | 1.0%    | -                      | -       | -                                              | -       | 30                    | 0.9%    |
| Unspecified, Carcinoma, NOS<br>(8010,8020-8022)       | 1,184     | 4.4%    | 977    | 4.4%    | 112   | 5.0%    | 77                     | 3.7%    | -                                              | -       | 164                   | 4.8%    |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>f</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

<sup>g</sup> Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

<sup>h</sup> Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

## Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Females by Race

| Histology <sup>a</sup>                                                                                                      | All Races |         | White  |         | Black |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|-----------------------------------------------------------------------------------------------------------------------------|-----------|---------|--------|---------|-------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                                                                             | Count     | Percent | Count  | Percent | Count | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Sarcoma and other soft tissue tumors<br>(8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9141-9340, 9540-9582)       | 91        | 0.3%    | 61     | 0.3%    | 20    | 0.9%    | -                      | -       | -                                              | -       | 20                    | 0.6%    |
| Other specific types<br>(8240-8246, 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9105, 9350-9364, 9380-9513, 9530-9539) | 1,874     | 7.0%    | 1,453  | 6.5%    | 222   | 9.9%    | 167                    | 7.9%    | -                                              | -       | 381                   | 11.0%   |
| Mullerian mixed tumor<br>(8950-8951, 8980)                                                                                  | 813       | 3.0%    | 684    | 3.1%    | 74    | 3.3%    | 45                     | 2.1%    | -                                              | -       | 80                    | 2.3%    |
| Teratoma, malignant<br>(9080-9085, 9102)                                                                                    | 415       | 1.5%    | 286    | 1.3%    | 64    | 2.8%    | 55                     | 2.6%    | -                                              | -       | 148                   | 4.3%    |
| Other                                                                                                                       | 646       | 2.4%    | 483    | 2.2%    | 84    | 3.7%    | 67                     | 3.2%    | -                                              | -       | 153                   | 4.4%    |
| Unspecified (8000-8005)                                                                                                     | 293       | 1.1%    | 233    | 1.0%    | 32    | 1.4%    | 22                     | 1.0%    | -                                              | -       | 42                    | 1.2%    |
| Total <sup>d</sup>                                                                                                          | 26,928    | 100.0%  | 22,272 | 100.0%  | 2,247 | 100.0%  | 2,107                  | 100.0%  | 134                                            | 100.0%  | 3,452                 | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

## Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Both Sexes by Race

| Histology <sup>a</sup>                               | All Races |         | White  |         | Black |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|------------------------------------------------------|-----------|---------|--------|---------|-------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                      | Count     | Percent | Count  | Percent | Count | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                            | 43,224    | 98.0%   | 34,469 | 98.0%   | 5,307 | 98.0%   | 3,085                  | 98.1%   | 180                                            | 98.9%   | 4,332                 | 97.7%   |
| Epidermoid carcinoma <sup>d</sup><br>(8051-8131)     | 107       | 0.2%    | 79     | 0.2%    | 16    | 0.3%    | -                      | -       | -                                              | -       | -                     | -       |
| Adenocarcinoma <sup>e</sup>                          | 37,839    | 85.8%   | 30,239 | 86.0%   | 4,597 | 84.8%   | 2,691                  | 85.6%   | 159                                            | 87.4%   | 3,773                 | 85.1%   |
| Adenocarcinoma, NOS<br>(8140)                        | 30,694    | 69.6%   | 24,489 | 69.6%   | 3,816 | 70.4%   | 2,128                  | 67.7%   | 137                                            | 75.3%   | 3,069                 | 69.2%   |
| Papillary adenocarcinoma,<br>NOS (8260)              | 43        | 0.1%    | 33     | 0.1%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Mucinous adenocarcinoma<br>(8480,8482)               | 1,151     | 2.6%    | 920    | 2.6%    | 127   | 2.3%    | 89                     | 2.8%    | -                                              | -       | 117                   | 2.6%    |
| Mucin-producing<br>adenocarcinoma (8481)             | 400       | 0.9%    | 332    | 0.9%    | 44    | 0.8%    | 23                     | 0.7%    | -                                              | -       | 37                    | 0.8%    |
| Infiltrating duct carcinoma<br>(8500-8503,8507,8514) | 4,392     | 10.0%   | 3,541  | 10.1%   | 460   | 8.5%    | 365                    | 11.6%   | -                                              | -       | 399                   | 9.0%    |
| Other adenocarcinoma <sup>f</sup>                    | 1,159     | 2.6%    | 924    | 2.6%    | 144   | 2.7%    | 82                     | 2.6%    | -                                              | -       | 144                   | 3.2%    |
| Other specific carcinomas <sup>g</sup>               | 3,115     | 7.1%    | 2,488  | 7.1%    | 370   | 6.8%    | 230                    | 7.3%    | -                                              | -       | 314                   | 7.1%    |
| Islet cell carcinoma<br>(8150-8155)                  | 344       | 0.8%    | 291    | 0.8%    | 34    | 0.6%    | -                      | -       | -                                              | -       | 30                    | 0.7%    |
| Other carcinomas <sup>h</sup>                        | 2,771     | 6.3%    | 2,197  | 6.2%    | 336   | 6.2%    | 215                    | 6.8%    | -                                              | -       | 284                   | 6.4%    |
| Unspecified, "Carcinoma, NOS"<br>(8010,8020-8022)    | 2,164     | 4.9%    | 1,664  | 4.7%    | 324   | 6.0%    | 153                    | 4.9%    | -                                              | -       | 240                   | 5.4%    |
| Sarcoma and other soft tissue<br>tumors <sup>i</sup> | 33        | 0.1%    | 27     | 0.1%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Other specific types <sup>j</sup>                    | 40        | 0.1%    | 32     | 0.1%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Unspecified (8000-8005)                              | 799       | 1.8%    | 634    | 1.8%    | 101   | 1.9%    | 56                     | 1.8%    | -                                              | -       | 91                    | 2.1%    |
| Total                                                | 44,098    | 100.0%  | 35,163 | 100.0%  | 5,418 | 100.0%  | 3,144                  | 100.0%  | 182                                            | 100.0%  | 4,435                 | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>f</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>g</sup> Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>h</sup> Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

<sup>i</sup> Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

<sup>j</sup> Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

<sup>k</sup> Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

## Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Both Sexes by Race

| Histology <sup>a</sup>                                                                                                                     | All Races |         | White  |         | Black |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|--------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|--------|---------|-------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                                                                                            | Count     | Percent | Count  | Percent | Count | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                                                                                                                  | 29,238    | 92.7%   | 20,894 | 93.3%   | 3,862 | 88.4%   | 4,041                  | 94.0%   | 209                                            | 95.0%   | 5,298                 | 95.6%   |
| Epidermoid carcinoma <sup>d</sup><br>(8051-8131)                                                                                           | 280       | 0.9%    | 197    | 0.9%    | 51    | 1.2%    | 27                     | 0.6%    | -                                              | -       | 26                    | 0.5%    |
| Squamous cell carcinoma<br>(8070-8078, 8083-8084)                                                                                          | 271       | 0.9%    | 191    | 0.9%    | 50    | 1.1%    | 25                     | 0.6%    | -                                              | -       | 23                    | 0.4%    |
| Adenocarcinoma<br>(8050, 8140-8147,<br>8160-8162, 8180-8221,<br>8250-8507, 8514, 8520-8551,<br>8560, 8570-8574,<br>8576, 8940-8941)        | 26,161    | 82.9%   | 18,578 | 82.9%   | 3,409 | 78.0%   | 3,828                  | 89.1%   | 182                                            | 82.7%   | 4,741                 | 85.5%   |
| Adenocarcinoma, NOS<br>(8140)                                                                                                              | 14,993    | 47.5%   | 11,069 | 49.4%   | 1,939 | 44.4%   | 1,802                  | 41.9%   | 100                                            | 45.5%   | 2,279                 | 41.1%   |
| Adenocarcinoma,<br>intestinal type (8144)                                                                                                  | 2,661     | 8.4%    | 1,580  | 7.1%    | 408   | 9.3%    | 634                    | 14.8%   | 26                                             | 11.8%   | 509                   | 9.2%    |
| Carcinoma, diffuse<br>type (8145)                                                                                                          | 1,153     | 3.7%    | 712    | 3.2%    | 143   | 3.3%    | 280                    | 6.5%    | -                                              | -       | 259                   | 4.7%    |
| Linitus plastica (8142)                                                                                                                    | 192       | 0.6%    | 149    | 0.7%    | 20    | 0.5%    | 20                     | 0.5%    | -                                              | -       | 53                    | 1.0%    |
| Mucinous adenocarcinoma<br>(8470-8473, 8480, 8482)                                                                                         | 437       | 1.4%    | 311    | 1.4%    | 63    | 1.4%    | 57                     | 1.3%    | -                                              | -       | 72                    | 1.3%    |
| Mucin-producing<br>adenocarcinoma (8481)                                                                                                   | 150       | 0.5%    | 113    | 0.5%    | 25    | 0.6%    | -                      | -       | -                                              | -       | 23                    | 0.4%    |
| Signet ring<br>adenocarcinoma (8490)                                                                                                       | 5,291     | 16.8%   | 3,752  | 16.7%   | 659   | 15.1%   | 797                    | 18.5%   | 39                                             | 17.7%   | 1,302                 | 23.5%   |
| Other adenocarcinomas <sup>e</sup>                                                                                                         | 1,284     | 4.1%    | 892    | 4.0%    | 152   | 3.5%    | 226                    | 5.3%    | -                                              | -       | 244                   | 4.4%    |
| Other specific carcinomas<br>(8012-8015, 8030-8046,<br>8150-8155, 8170-8175,<br>8230-8249, 8508, 8510-8513,<br>8561-8562, 8575, 8580-8671) | 2,086     | 6.6%    | 1,612  | 7.2%    | 296   | 6.8%    | 105                    | 2.4%    | 18                                             | 8.2%    | 421                   | 7.6%    |
| Unspecified, Carcinoma, NOS<br>(8010-8011, 8020-8022)                                                                                      | 711       | 2.3%    | 507    | 2.3%    | 106   | 2.4%    | 81                     | 1.9%    | -                                              | -       | 110                   | 2.0%    |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>e</sup> Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

## Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005  
Both Sexes by Race

| Histology <sup>a</sup>                                                                                                        | All Races |         | White  |         | Black |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|-------------------------------------------------------------------------------------------------------------------------------|-----------|---------|--------|---------|-------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                                                                               | Count     | Percent | Count  | Percent | Count | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Sarcoma and other soft tissue tumors (8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582) | 76        | 0.2%    | 57     | 0.3%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Other specific types (8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539)                            | 2,074     | 6.6%    | 1,340  | 6.0%    | 475   | 10.9%   | 237                    | 5.5%    | -                                              | -       | 197                   | 3.6%    |
| Unspecified (8000-8005)                                                                                                       | 156       | 0.5%    | 112    | 0.5%    | 21    | 0.5%    | 16                     | 0.4%    | -                                              | -       | 36                    | 0.6%    |
| Total <sup>d</sup>                                                                                                            | 31,544    | 100.0%  | 22,403 | 100.0%  | 4,371 | 100.0%  | 4,298                  | 100.0%  | 220                                            | 100.0%  | 5,542                 | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

## Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012  
Both Sexes by Race

| Histology <sup>a</sup>                                          | All Races |         | White  |         | Black |         | Asian/Pacific Islander |         | American Indian/<br>Alaska Native <sup>b</sup> |         | Hispanic <sup>c</sup> |         |
|-----------------------------------------------------------------|-----------|---------|--------|---------|-------|---------|------------------------|---------|------------------------------------------------|---------|-----------------------|---------|
|                                                                 | Count     | Percent | Count  | Percent | Count | Percent | Count                  | Percent | Count                                          | Percent | Count                 | Percent |
| Carcinoma                                                       | 58,629    | 99.7%   | 47,625 | 99.7%   | 3,893 | 99.5%   | 5,874                  | 99.7%   | 260                                            | 100.0%  | 8,784                 | 99.7%   |
| Epidermoid carcinoma <sup>d</sup><br>(8051-8131)                | 57        | 0.1%    | 43     | 0.1%    | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Adenocarcinoma <sup>e</sup>                                     | 56,674    | 96.3%   | 46,039 | 96.4%   | 3,716 | 95.0%   | 5,719                  | 97.1%   | 253                                            | 97.3%   | 8,510                 | 96.6%   |
| Papillary adenocarcinoma<br>(8050,8260,8340-8344,<br>8350,8450) | 52,060    | 88.5%   | 42,415 | 88.8%   | 3,200 | 81.8%   | 5,345                  | 90.7%   | 230                                            | 88.5%   | 7,912                 | 89.8%   |
| Follicular carcinoma<br>(8330-8332,8335)                        | 3,011     | 5.1%    | 2,303  | 4.8%    | 368   | 9.4%    | 271                    | 4.6%    | -                                              | -       | 418                   | 4.7%    |
| Oxyphilic (8290)                                                | 1,303     | 2.2%    | 1,090  | 2.3%    | 111   | 2.8%    | 77                     | 1.3%    | -                                              | -       | 147                   | 1.7%    |
| Other specific carcinomas <sup>f</sup>                          | 1,055     | 1.8%    | 889    | 1.9%    | 96    | 2.5%    | 50                     | 0.8%    | -                                              | -       | 163                   | 1.8%    |
| Medullary carcinoma (8510)                                      | 1,023     | 1.7%    | 860    | 1.8%    | 93    | 2.4%    | 50                     | 0.8%    | -                                              | -       | 159                   | 1.8%    |
| Carcinoma, NOS<br>(8004,8010-8012,<br>8020-8022,8030-8032)      | 843       | 1.4%    | 654    | 1.4%    | 76    | 1.9%    | 96                     | 1.6%    | -                                              | -       | 106                   | 1.2%    |
| Anaplastic carcinoma<br>(8004,8012,8020-8021,<br>8030-8032)     | 499       | 0.8%    | 402    | 0.8%    | 40    | 1.0%    | 55                     | 0.9%    | -                                              | -       | 63                    | 0.7%    |
| Sarcoma and other soft tissue<br>tumors <sup>g</sup>            | -         | -       | -      | -       | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Other specific types <sup>h</sup>                               | -         | -       | -      | -       | -     | -       | -                      | -       | -                                              | -       | -                     | -       |
| Unspecified (8000-8003,8005)                                    | 176       | 0.3%    | 135    | 0.3%    | 16    | 0.4%    | 17                     | 0.3%    | -                                              | -       | 25                    | 0.3%    |
| Total                                                           | 58,828    | 100.0%  | 47,779 | 100.0%  | 3,913 | 100.0%  | 5,891                  | 100.0%  | 260                                            | 100.0%  | 8,814                 | 100.0%  |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>f</sup> Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>g</sup> Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

<sup>h</sup> Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

<sup>i</sup> Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.